These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29912633)

  • 1. ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer.
    Zhang Y; Bi J; Zhu H; Shi M; Zeng X
    Biosci Biotechnol Biochem; 2018 Oct; 82(10):1733-1741. PubMed ID: 29912633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
    Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
    J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annexin A2 depletion delays EGFR endocytic trafficking via cofilin activation and enhances EGFR signaling and metastasis formation.
    de Graauw M; Cao L; Winkel L; van Miltenburg MH; le Dévédec SE; Klop M; Yan K; Pont C; Rogkoti VM; Tijsma A; Chaudhuri A; Lalai R; Price L; Verbeek F; van de Water B
    Oncogene; 2014 May; 33(20):2610-9. PubMed ID: 23792445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
    El Guerrab A; Bamdad M; Kwiatkowski F; Bignon YJ; Penault-Llorca F; Aubel C
    Oncotarget; 2016 Nov; 7(45):73618-73637. PubMed ID: 27655662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance and mechanism of STAT3/miR-221-3p/Fascin-1 axis in EGFR TKI resistance of triple-negative breast cancer.
    Jin LL; Lu HJ; Shao JK; Wang Y; Lu SP; Huang BF; Hu GN; Jin HC; Wang CQ
    Mol Cell Biochem; 2024 Nov; 479(11):3037-3047. PubMed ID: 38145448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
    Yi Y; Zeng S; Wang Z; Wu M; Ma Y; Ye X; Zhang B; Liu H
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):793-803. PubMed ID: 29253515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
    Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
    Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ANXA2 (annexin A2) is crucial to ATG7-mediated autophagy, leading to tumor aggressiveness in triple-negative breast cancer cells.
    Koh M; Lim H; Jin H; Kim M; Hong Y; Hwang YK; Woo Y; Kim ES; Kim SY; Kim KM; Lim HK; Jung J; Kang S; Park B; Lee HB; Han W; Lee MS; Moon A
    Autophagy; 2024 Mar; 20(3):659-674. PubMed ID: 38290972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells.
    Fan Y; Si W; Ji W; Wang Z; Gao Z; Tian R; Song W; Zhang H; Niu R; Zhang F
    Breast Cancer Res; 2019 May; 21(1):66. PubMed ID: 31113450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
    Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
    Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
    Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
    Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies.
    Chaudhary P; Thamake SI; Shetty P; Vishwanatha JK
    Br J Cancer; 2014 Dec; 111(12):2328-41. PubMed ID: 25321192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyr23 phosphorylation of Anxa2 enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells.
    Yuan J; Yang Y; Gao Z; Wang Z; Ji W; Song W; Zhang F; Niu R
    Breast Cancer Res Treat; 2017 Jul; 164(2):327-340. PubMed ID: 28470457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
    J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.